Leading up to the Brisbane event on Tuesday.
Please review the minutes from the Sydney & Melbourne meetings and post here below some questions of a similar nature and content or clarification perhaps of those discussed in Melbourne & Sydney and please no tangential topics!
Thanks so much
@rusty02Sydney
Minutes Of MeetingMore news flow in the coming weeksRobert Clarke; Instimental in his DD on the company and an intregal part of fast tracking regletory and FDA obligationsOverseeing and working towards T/O and acquisitions but with an overall bussiness plan aiming at commercialisation and marketing.28 assets developed in houseAll with a distinct focus on reglatory obligations, commercialisation and marketing our assetsHiring Heat of Corporate Development officer to oversee and concentrate on quick commercialisation of each assetsIHL42XApproval from FDA massive acheivement in this short time via RC expertise.47 sites 400-600 patientsAccessable market of $10bnTrials to start in November once final reglatory obligations met52 week trial with interum updates to the market at 3, 6 and 12 monthsRestmed showing interest and IHL42X could be acquired before product design and marketing but still focused on the bussiness model to bring all assets to the market.Restmed efficency on CPAP 46% IHL42X just under 60% 25% patients at 82% and 1 at 90%No linguring side effectsPSI GADAll applications nearing completionCommited to manufacture and product designFDA 4th qtrIHL675ACurrent phase 2 120 patientsUpdates and interums 4 qtrGumCanQuite N 5.2bn marketCanQuite O 64bn marketRennecan Dermatology Massive market6 EDA/EMA underwayPre IND by xmasProduct design underwayClinicsMany patient enquiriesClinic ready in coming days and aiming at patient intake next monthMulti Bn market in Australia aloneWorld eyes are watching this space.World leaders with Dr PL at the helm and highly regarded via MonarchCashflow positive very quickly with further clinics to open swiftlyRedomicileMaximise assets in the USLiquidity tight under current platform for larger US investors to take positionsBetter CR opportunities due to more depth in liquidityEasier for T/O or acquisitionsMother company Delware to safeguard any hostile T/O or Acquisitions.US share registry have been commissioned for the transitionAustralian investorrs will be notified once redomiciled/transfer and a start up trading platform can be opened for trading direct through the US registry or choose their own broker.Joel is activily finalising for SMSF to transfer into US entityHugh CR platform for Joel in the coming months with US interest.R and D to stay in Australia. Government funded R and D programs to 47% expenditure.Voting to be held some time in late October with swift Transfer within a week after shareholder approvalAiming at early Novermber Transfer after a 2 week Traded Hault for US NASDAQ commission and to give shareholders time to set up their trading plateforms.Joel and team were awesome.Well articulated presentation, open to all questions, precise with a solid game plan to gain traction in the share price and move our assets into commercialisation.The underlying factor underpinning our assets is the hugh potential for a T/O or Acquisition. Placing IHL amoungst its peers with market Caps at multipules of where IHL is and with far less assets, market access and portfolio diversification.I had a good 1hr+ chat with Joel and his dedication drive and passion for IHL and their shareholders is increadable. Yes we will have some pain in the SP during this redomicile period but come November its all systems go. The critisism about Joel on HC is totally unfounded and one needs to look at fundamentals, what the company is doing and acheiving behind the scenes and the wealth of expertise the team have all experts in their feild and second to non. IHL are truely world class and ahead of their compeditors.GLAH
---------------------------------------------------------------------------------------------------------------
Thanks so much, @von for;IHL Shareholders meeting Melbourne 24 August 23
Masses of information and moving parts, shared last night. So apologies if not all correct.
Was keen to get a “feel” for the team, and their ability to successfully manage cross border, time zones, fast pace, and multiple projects.
Joel very pumped, articulate, and driven, but feel there is good balance from Chairman (Troy Valentine) and no doubt other Board Members. Additional resources being added. Head of Corporate Development (USA based), will concentrate on Co-funding, Outsourcing, Joint Development, Acquisition
Three way confirmation of the value of Bob Clark.
- Due the extensive due diligence he conducted before agreeing to join (am sure he would have had many other global offers)
- Has not been on any other Boards (outside his employer)
- Has a significant track record in successful FDA/IND submissions. 35 years in the game and a 15/15 hit rate. He is incentivised to get results
- Good to see focus on key assets, with structured project management teams allocated
- AUD research and development remains, enabling R &D Tax breaks on well resourced and managedprojects (and can’t help thinking this would be an attractive piece for partner/acquirer)
- Clarion Clinics has had excellent patient enquiry response, PR campaign about to ramp up in this area, and assumptions about profit margin looking good.
- Top 40 shareholders hold 47% of company.
- For Redomicile on Nasdaq: IXL need to get shareholder vote across the line.
- Alternative (delisting (ASX) without shareholder support) not palatable, but IHL is not staying on ASX - multiple reasons for others to expand on.
- Important for holders to ensure Automic has current email, contact telephone and postal address for information to be sent.
- Work in progress to make transition to NASDAQ as seamless as possible. A full recommendation about USA share registry/broker, tax information from Pitcher Partners and other requirements, will be released shortly in a package.
- Lots building behind the scenes for release post Nasdaq listing
- Among other things first time attending JP MORGAN Annual Healthcare Conference will take place on January 8-11, 2024 in San Francisco, CA. (Appears to be a significant showcase opportunity)
-----------------------------------------------------------------------------------
Glah and see some of you from 4pm?
Date:29th August
Time:Commencing at 6:00 PM
Location:Studio 3 , W Hotel Brisbane
Address:W Hotel Brisbane, 81 North Quay, Brisbane, Queensland 4000
https://hotcopper.com.au/threads/ann-ihl-provides-shareholder-information-events-for-redomiciling.7518526/page-65?post_id=69452895Have a good week
